DDInter1843 DDInter856
Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Trandolapril {u} (Compound) resembles {v} (Compound) Mitiglinide
Trandolapril {u} (Compound) treats {v} (Disease) coronary artery disease
Trandolapril {u} (Compound) binds {v} (Gene) ACE
Trandolapril {u} (Compound) causes {v} (Side Effect) Dysgeusia
Trandolapril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darbepoetin alfa
Trandolapril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium bicarbonate
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iloprost
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegaspargase
Trandolapril {u} may lead to a major life threatening interaction when taken with {v} Potassium gluconate
Trandolapril {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Trandolapril (Compound) resembles Mitiglinide (Compound)
Trandolapril (Compound) treats coronary artery disease (Disease)
Trandolapril (Compound) binds ACE (Gene)
Trandolapril (Compound) causes Dysgeusia (Side Effect)
Trandolapril may cause a minor interaction that can limit clinical effects when taken with Darbepoetin alfa
Trandolapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Trandolapril may lead to a major life threatening interaction when taken with Potassium gluconate
Trandolapril (Compound) resembles Nateglinide (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide